Skip to main content

Advertisement

Table 2 Assessment of treatments for efficacy in glycemic control in the 2 groups

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Variables 0 week 12 weeks 24 weeks
HbA1c (%)    
The group A 9.3 ± 1.5 8.2 ± 1.2* 7.3 ± 1.3**
The group B 9.4 ± 1.4 8.6 ± 1.3* 7.9 ± 1.3*#
FBG (mmol/L)    
The group A 11.4 ± 2.4 7.6 ± 1.8** 6.9 ± 1.3**
The group B 11.3 ± 2.6 8.2 ± 2.1** 7.7 ± 1.6**#
P2BG (mmol/L)    
The group A 16.8 ± 4.4 11.2 ± 2.3** 8.6 ± 2.1**
The group B 17.0 ± 4.5 12.4 ± 2.3** 10.8 ± 2.2**#
Insulin dose (unit/day)    
The group A 68.6 ± 14.6 44.8 ± 15.9** 32.3 ± 14.9**
The group B 66.8 ± 13.9 79.3 ± 14.8* 86.2 ± 18.9**##
Body Weight (kg)    
The group A 66.2 ± 16.3 66.4 ± 16.5 66.9 ± 16.6
The group B 67.2 ± 15.9 68.3 ± 16.0 69.8 ± 16.5**#
  1. Data expressed mean ± SD; HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; *p < 0.05 vs. baseline, **p < 0.01 vs. baseline. #p < 0.05 group A vs. group B, ##p < 0.01 group A vs. group B.